<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300313</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-06-3913-JZ-CTIL</org_study_id>
    <nct_id>NCT00300313</nct_id>
  </id_info>
  <brief_title>PTSD Prevention Using Escitalopram</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <brief_summary>
    <textblock>
      Assessing the efficacy of escitalopram in preventing the development of PTSD, or or reducing
      its severeness, after exposure to a traumatic event.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CAPS</measure>
    <time_frame>1-year follow-up</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Post-traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>10 to 20 mg / day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1-2 capsules</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient is able to read and understand the Patient Informed Consent.

          2. The patient has signed the Patient Informed Consent.

          3. The patient has sufficient knowledge of Hebrew in order to understand the study
             procedure and instruments

          4. The patient is male or female aged between 18 and 65 years (extremes included).

          5. The patient underwent a traumatic event, such as vehicle or other accident, terror
             attack, physical or sexual assault within the last 3 weeks, and no more than 4 weeks
             ago.

          6. The patient meets either of the following criteria:

        1. Full DSM-IV criteria for ASD 2. Intrusion and hyperarousal criteria only

        Exclusion Criteria:

          1. The patient refuses having any medication therapy. This patient will be referred to
             another treatment outside the study frame.

          2. The patient has a serious physical injury at inclusion, in which his Abbreviated
             Injury Scale (AIS) score, for at least one of his body regions, is 3 or more, or that
             according to the judgment of the clinician his injury sequelae would interfere with
             the study treatment.

          3. The patient uses concomitant medications not allowed in the study:

               1. Antidepressants, including MAOI, RIMA within the last 3 weeks prior to screening.

               2. Mood stabilizers within the last 3 weeks prior to screening.

               3. Antipsychotic medications within the last 3 weeks prior to screening.

               4. Anxiolytics 2 weeks in a row before randomization. Patient can participate in the
                  study if did not take the medications for 3 days over the two weeks before
                  randomization. Except for oxazepam 10-20 mg/day no more than 7 days in a raw.

               5. Serotonergic agonists (e.g. triptans) within the last 2 weeks prior to screening.

               6. Prophylactic treatment with any anticonvulsant drug.

               7. Herbal remedies that are psychoactive (e.g. St John's Wort, Kava kava, valerian,
                  gingko biloba) within the last 3 weeks prior to screening.

          4. The patient meets lifetime DSM-IV-TR criteria for:

               1. Mania or Bipolar disorder

               2. Schizophrenia

               3. Any personality disorder judged by the investigator to jeopardize the evaluation
                  of the treatment.

               4. Mental retardation or pervasive disorder

               5. Cognitive disorder (inc. dementia)

          5. The patient has or has had alcohol or drug abuse related disorders in the last year
             prior to the screening visit.

          6. The patient has, in the investigator's opinion, significant suicide risk and/or a
             score of â‰¥ 5 on question 10 in the MADRS scale.

          7. The patient has a history of severe suicide attempt.

          8. The patient requires ElectroConvulsive Therapy (ECT) or has received ECT within the
             last year prior to the screening visit.

          9. The patient is currently serving in the Israeli security forces.

         10. The patient has a history of drug allergy or hypersensitivity, or known
             hypersensitivity to escitalopram or citalopram.

         11. The patient has an illness and/or serious sequelae thereof, severe enough according to
             the clinician judgment, to prevent his participation in the study, including liver or
             renal insufficiency; cardiovascular, pulmonary, gastrointestinal, endocrine (inc.
             uncontrolled thyroid), neurological (inc. epilepsy), infectious, neoplastic, or
             metabolic disturbances

         12. The patient is pregnant or breast-feeding.

         13. The patient, if woman of childbearing potential, is not using adequate contraception
             (adequate contraception is defined as sexual abstinence, oral/systemic contraception,
             surgical sterilisation, intrauterine device, diaphragm in combination with spermicide,
             or condom for male partner in combination with spermicide).

         14. The patient, in the opinion of the investigator, is unlikely to comply with the
             clinical study protocol.

         15. The patient has previously participated in the current study or in any other study
             within the last 30 days.

         16. The patient has familial relationships with the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Zohar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RAMBAM Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassa Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2006</study_first_submitted>
  <study_first_submitted_qc>March 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2006</study_first_posted>
  <last_update_submitted>December 30, 2013</last_update_submitted>
  <last_update_submitted_qc>December 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Prof. Joseph Zohar</investigator_full_name>
    <investigator_title>Prof. Joseph Zohar</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

